Grifols sees revenues rise after diagnostics boost
This article was originally published in Clinica
Executive Summary
Spain’s largest healthcare company Grifols saw sales increase by around 15% during the first nine months of 2009 after it was boosted by increased revenue from its diagnostics division. The firm recorded a 20% increase in diagnostics sales to €76.2m ($114.1m) during the nine-month period. Sales of Grifols’ reagents were the main drivers behind this increase. The group, which also develops pharma products, recorded overall revenue for the nine months of €689.6m, up from €600.2m during the same period the previous year. Overall net profit for the period was €117.1m, an improvement on €92.9m recorded in the first nine months of 2008.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals